Background:Given the variability across populations and settings, defining the MCID and the PASS for the Rowe and ASOSS scores and patients undergoing primary and revision Latarjet it is essential to have accurate benchmarks relevant to these groups when interpreting clinical results.Purpose:To determine the minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) thresholds for the visual analog scale (VAS) for pain during sports, Athletic Shoulder Outcome Scoring System (ASOSS), and Rowe scores after primary and revision Latarjet procedures for treatment of shoulder instability.Study Design:Cohort study (diagnosis); Level of evidence, 3.Methods:Between January 2018 and January 2020, a retrospective review of 149 patients undergoing primary Latarjet (n = 82) and revision Latarjet (n = 67) to treat shoulder instability was performed in a single institution. Patient-reported outcome measures were collected preoperatively and 1 year postoperatively. The delta was defined as the change between the pre- and postoperative scores. Distribution-based and anchored-based approaches were used to estimate the MCID and the PASS, respectively. The optimal cutoff point and the percentage of patients achieving those thresholds were also calculated.Results:The distribution-based MCIDs after primary Latarjet were 1.1, 7.5, and 9.6 for the VAS, Rowe, and ASOSS scores, respectively. The rates of patients who achieved the MCID thresholds were 93.9%, 98.7%, and 100% for the VAS, Rowe, and ASOSS scores, respectively. The PASS thresholds after primary Latarjet were ≤1, ≥90, and ≥85 for the VAS, Rowe, and ASOSS scores, respectively. The percentages of patients who achieved PASS thresholds were 82.9%, 89%, and 86.5% for the VAS, Rowe, and ASOSS scores, respectively. The distribution-based MCIDs after revision Latarjet were 0.6, 6.2, and 3.4 for the VAS, Rowe, and ASOSS scores, respectively. The rates of patients who achieved MCID thresholds were 89.3%, 100%, and 100% for the VAS, Rowe, and ASOSS scores, respectively. The PASS thresholds were ≤3, ≥87, and ≥86 after revision Latarjet for the VAS, Rowe, and ASOSS scores, respectively. The rates of patients who achieved the PASS thresholds were 88%, 88%, and 91% for the VAS, Rowe, and ASOSS, respectively.Conclusion:This study identified useful values for the MCID and PASS thresholds in VAS, Rowe, and ASOSS scores after primary and revision Latarjet procedures for treating shoulder instability. Most patients achieved MCID and PASS benchmarks, indicating successful primary and revision Latarjet procedure outcomes. These metrics can serve as valuable parameters when analyzing parameters in future studies and have the potential to enhance patient care by optimizing treatment strategies and surgical decision making.

中文翻译：

---

初步和修订 Latarjet 手术的临床意义阈值具有可比较的结果

背景：考虑到不同人群和环境的差异，定义 Rowe 和 ASOSS 评分的 MCID 和 PASS 以及接受初次和翻修 Latarjet 的患者，在解释临床结果时必须有与这些群体相关的准确基准。目的：确定运动期间疼痛视觉模拟量表 (VAS) 的最小临床重要差异 (MCID) 和患者可接受的症状状态 (PASS) 阈值、运动肩部结果评分系统 (ASOSS) 以及初次和修订 Latarjet 手术后的 Rowe 评分研究设计：队列研究（诊断）；证据水平，3.方法：2018 年 1 月至 2020 年 1 月期间，在同一机构对 149 名接受初次 Latarjet (n = 82) 和翻修 Latarjet (n = 67) 治疗肩部不稳的患者进行了回顾性评价。术前和术后 1 年收集患者报告的结果指标。增量被定义为术前和术后评分之间的变化。基于分布和锚定的方法分别用于估计 MCID 和 PASS。还计算了最佳截止点和达到这些阈值的患者百分比。结果：初次 Latarjet 后，VAS、Rowe 和 ASOSS 评分的基于分布的 MCID 分别为 1.1、7.5 和 9.6。 VAS、Rowe 和 ASOSS 评分达到 MCID 阈值的患者比例分别为 93.9%、98.7% 和 100%。初次 Latarjet 后 VAS、Rowe 和 ASOSS 评分的 PASS 阈值分别为 ≤1、≥90 和 ≥85。 VAS、Rowe 和 ASOSS 评分达到 PASS 阈值的患者百分比分别为 82.9%、89% 和 86.5%。 Latarjet 修订后，VAS、Rowe 和 ASOSS 评分的基于分布的 MCID 分别为 0.6、6.2 和 3.4。 VAS、Rowe 和 ASOSS 评分达到 MCID 阈值的患者比例分别为 89.3%、100% 和 100%。 Latarjet 修订后，VAS、Rowe 和 ASOSS 评分的 PASS 阈值分别为 ≤3、≥87 和 ≥86。 VAS、Rowe 和 ASOSS 达到 PASS 阈值的患者比例分别为 88%、88% 和 91%。结论：本研究确定了 VAS、Rowe 和 ASOSS 中 MCID 和 PASS 阈值的有用值用于治疗肩部不稳定的初次和修正 Latarjet 手术后的评分。大多数患者达到了 MCID 和 PASS 基准，表明初次和翻修 Latarjet 手术结果成功。这些指标可以在未来研究中分析参数时作为有价值的参数，并有可能通过优化治疗策略和手术决策来加强患者护理。